Quick answers
- What is Aromasin?
- Aromasin is a brand name of Exemestane, a prescription medicine. The FDA NDC Directory lists 1 Aromasin product in 1 strength and form.
- Who makes Aromasin?
- Pfizer holds the FDA application for Aromasin (NDA020753, approved October 21, 1999).
- Is there a generic or store brand of Aromasin?
- Yes. The FDA NDC Directory lists 4 other products with the same active ingredients, strength and form as a Aromasin product, 4 of them generic. Ask your pharmacist whether one is right for you.
- What do pharmacies pay for Aromasin?
- CMS lists a National Average Drug Acquisition Cost (NADAC) for 1 Aromasin strength and form (see the table below). That is what pharmacies pay to buy it, not what you pay: your price depends on your insurance and your pharmacy.
- Has Aromasin been recalled?
- No recall linked to Aromasin products (by their NDC code or label) appears in the FDA enforcement reports we use.
What Aromasin is
Each Aromasin product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.
Exemestane · prescription medicine
| Strength and form | Product names | Same medicine, other names | Label |
|---|---|---|---|
| exemestane 25 mg tablet (oral) | Aromasin | 4 products, 4 companies | DailyMed |
Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Exemestane →
FDA approval
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Holder | First approved | Products |
|---|---|---|---|
| NDA020753 | Pfizer | October 21, 1999 | 1 |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| exemestane 25 mg tablet | Brand: Aromasin | $38.98 per tablet Generic of the same strength and form: $0.6303 per tablet |
NADAC list of November 4, 2026; these prices took effect on January 1, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list Aromasin
The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Aromasin products.
- Pharmacia & Upjohn Company LLC1 product
Recalls
No recall linked to Aromasin products (by their NDC code or label) appears in the FDA enforcement reports.
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026
Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.